Mural Oncology plc (NASDAQ:MURA) — Market Cap & Net Worth
Market Cap & Net Worth: Mural Oncology plc (MURA)
Mural Oncology plc (NASDAQ:MURA) has a market capitalization of $35.38 Million ($35.38 Million) as of May 4, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #23138 globally and #4811 in its home market, demonstrating a 0.49% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Mural Oncology plc's stock price $2.04 by its total outstanding shares 17344486 (17.34 Million). Analyse Mural Oncology plc operating cash flow efficiency to see how efficiently the company converts income to cash.
Mural Oncology plc Market Cap History: 2023 to 2025
Mural Oncology plc's market capitalization history from 2023 to 2025. Data shows change from $102.68 Million to $35.38 Million (-26.00% CAGR).
Index Memberships
Mural Oncology plc is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.41 Trillion | 0.00% | #660 of 976 |
|
NASDAQ Composite
IXIC
|
$38.77 Trillion | 0.00% | #2211 of 3165 |
Weight: Mural Oncology plc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Mural Oncology plc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Mural Oncology plc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of MURA by Market Capitalization
Companies near Mural Oncology plc in the global market cap rankings as of May 4, 2026.
Key companies related to Mural Oncology plc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #223 globally with a market cap of $107.56 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #367 globally with a market cap of $72.88 Billion USD.
- UCB SA (BR:UCB): Ranked #517 globally with a market cap of $51.45 Billion USD ( €44.01 Billion EUR).
- argenx NV ADR (NASDAQ:ARGX): Ranked #568 globally with a market cap of $45.97 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #223 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $107.56 Billion | $423.92 |
| #367 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $72.88 Billion | $701.42 |
| #517 | UCB SA | BR:UCB | $51.45 Billion | €231.20 |
| #568 | argenx NV ADR | NASDAQ:ARGX | $45.97 Billion | $787.95 |
Mural Oncology plc Historical Marketcap From 2023 to 2025
Between 2023 and today, Mural Oncology plc's market cap moved from $102.68 Million to $ 35.38 Million, with a yearly change of -26.00%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | $35.38 Million | -36.65% |
| 2024 | $55.85 Million | -45.61% |
| 2023 | $102.68 Million | -- |
End of Day Market Cap According to Different Sources
On May 4th, 2026 the market cap of Mural Oncology plc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $35.38 Million USD |
| MoneyControl | $35.38 Million USD |
| MarketWatch | $35.38 Million USD |
| marketcap.company | $35.38 Million USD |
| Reuters | $35.38 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Mural Oncology plc
Mural Oncology plc operates as a clinical-stage oncology company that focuses on discovering and developing immunotherapies for the treatment of patients with cancer. The company's lead product candidate includes nemvaleukin alfa for the treatment of mucosal melanoma as a monotherapy and platinum-resistant ovarian cancer in combination with pembrolizumab. It also develops nemvaleukin to treat cut… Read more